Reply to correspondence on "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy".
作者信息
Gedallovich Seren M, Kwo Paul Y
机构信息
Division of Gastroenterology and Hepatology, Stanford University Medical School, Stanford, CA, USA.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):1050-1052. doi: 10.3350/cmh.2024.0546. Epub 2024 Jul 12.
Abstract
摘要
相似文献
1
Reply to correspondence on "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy".对关于“二甲双胍和他汀类药物降低抗病毒治疗失败的慢性丙型肝炎患者肝细胞癌风险”的信件的回复
Clin Mol Hepatol. 2024 Oct;30(4):1050-1052. doi: 10.3350/cmh.2024.0546. Epub 2024 Jul 12.
2
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.二甲双胍和他汀类药物可降低抗病毒治疗失败的慢性丙型肝炎患者肝细胞癌的风险。
Clin Mol Hepatol. 2024 Jul;30(3):468-486. doi: 10.3350/cmh.2024.0038. Epub 2024 Apr 19.
3
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy".二甲双胍和他汀类药物及其在降低肝细胞癌风险中的作用：需要进行随机试验：关于“二甲双胍和他汀类药物可降低抗病毒治疗失败的慢性丙型肝炎患者的肝细胞癌风险”的社论
Clin Mol Hepatol. 2024 Oct;30(4):714-717. doi: 10.3350/cmh.2024.0425. Epub 2024 Jun 11.
4
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.在台湾，二甲双胍可降低糖尿病合并慢性丙型肝炎患者抗病毒治疗成功后的肝细胞癌发病率。
J Hepatol. 2023 Feb;78(2):281-292. doi: 10.1016/j.jhep.2022.09.019. Epub 2022 Oct 5.
5
Additional Inhibition of Wnt/β-Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients.二甲双胍在 DAA 治疗中对 Wnt/β-连环蛋白信号的额外抑制作用是 HCV 感染患者的一种新的治疗策略。
Cells. 2021 Apr 2;10(4):790. doi: 10.3390/cells10040790.
6
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.直接作用抗病毒 HCV 治疗后肝细胞癌风险：系统评价、荟萃分析和荟萃回归。
J Hepatol. 2017 Dec;67(6):1204-1212. doi: 10.1016/j.jhep.2017.07.025. Epub 2017 Aug 9.
7
[The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].[直接抗病毒治疗对丙型肝炎病毒相关肝细胞癌诊断的影响]
Nihon Shokakibyo Gakkai Zasshi. 2018;115(2):184-194. doi: 10.11405/nisshoshi.115.184.
8
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.根治性治疗肝细胞癌后，对于肝功能储备降低的晚期肝细胞癌患者，清除丙型肝炎病毒的疗效：日本红十字会肝脏研究组的一项全国性多中心研究。
J Viral Hepat. 2022 Jul;29(7):551-558. doi: 10.1111/jvh.13684. Epub 2022 May 18.
9
The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.直接抗病毒药物清除丙型肝炎病毒后细胞因子变化对肝细胞癌风险的影响。
J Formos Med Assoc. 2021 Mar;120(3):965-973. doi: 10.1016/j.jfma.2020.10.015. Epub 2020 Oct 29.
10
The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.直接作用抗病毒药物对根治性治疗后丙型肝炎病毒相关肝细胞癌的影响。
Invest New Drugs. 2020 Feb;38(1):202-210. doi: 10.1007/s10637-019-00870-9. Epub 2019 Nov 8.
本文引用的文献
1
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".直接抗病毒药物（DAA）时代后丙型肝炎病毒清除后肝细胞癌的风险及分子机制：对“直接抗病毒药物时代未满足的需求：丙型肝炎病毒清除后肝细胞癌的风险及分子机制”社论的回应
Clin Mol Hepatol. 2024 Oct;30(4):1023-1025. doi: 10.3350/cmh.2024.0472. Epub 2024 Jul 1.
2
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy".二甲双胍和他汀类药物及其在降低肝细胞癌风险中的作用：需要进行随机试验：关于“二甲双胍和他汀类药物可降低抗病毒治疗失败的慢性丙型肝炎患者的肝细胞癌风险”的社论
Clin Mol Hepatol. 2024 Oct;30(4):714-717. doi: 10.3350/cmh.2024.0425. Epub 2024 Jun 11.
3
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.二甲双胍和他汀类药物可降低抗病毒治疗失败的慢性丙型肝炎患者肝细胞癌的风险。
Clin Mol Hepatol. 2024 Jul;30(3):468-486. doi: 10.3350/cmh.2024.0038. Epub 2024 Apr 19.
4
Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort.多中心队列中肝细胞癌监测的障碍。
JAMA Netw Open. 2022 Jul 1;5(7):e2223504. doi: 10.1001/jamanetworkopen.2022.23504.
5
Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.一种新型多靶点血液检测方法的验证显示其对早期肝细胞癌具有高灵敏度。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):173-182.e7. doi: 10.1016/j.cgh.2021.08.010. Epub 2021 Aug 13.
6
Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.多伊尔斯敦 PLUS 和 GALAD 在肝硬化患者中 HCC 检测具有高灵敏度。
Clin Gastroenterol Hepatol. 2022 Apr;20(4):953-955.e2. doi: 10.1016/j.cgh.2021.04.018. Epub 2021 Apr 20.
7
Metabolic disease as a risk of hepatocellular carcinoma.代谢性疾病作为肝细胞癌的一种风险因素。
Clin Mol Hepatol. 2021 Jan;27(1):87-90. doi: 10.3350/cmh.2020.0302. Epub 2020 Dec 3.
8
Alcohol and hepatocarcinogenesis.酒精与肝癌发生。
Clin Mol Hepatol. 2020 Oct;26(4):736-741. doi: 10.3350/cmh.2020.0203. Epub 2020 Oct 1.
9
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.生活方式和环境措施在原发性肝细胞癌的一级预防中的作用。
Clin Liver Dis. 2020 Nov;24(4):549-576. doi: 10.1016/j.cld.2020.06.002. Epub 2020 Aug 25.
10
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.aMAP 风险评分可预测慢性肝炎患者发生肝细胞癌的风险。
J Hepatol. 2020 Dec;73(6):1368-1378. doi: 10.1016/j.jhep.2020.07.025. Epub 2020 Jul 21.
Zotero 插件